特定基因组架构将增强剂和非编码性疾病变异与基因促进剂联系起来
Biola M Javierre1, Oliver S Burren2, Steven P Wilder3
1Nuclear Dynamics Programme, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.
Cell
|November 19, 2016
概括
这项研究绘制了人体血液细胞中的基因促进物相互作用图,揭示了细胞特异性调节网络. 这些发现将遗传变异与疾病联系起来, 进步我们对基因组控制的理解.
科学领域:
- 基因组学
- 分子生物学
- 表观遗传学
背景情况:
- 调节元件和基因促进体之间的长距离相互作用对于转录调节至关重要.
- 大多数这些关键的相互作用仍然未被描述,阻碍了对基因组控制的完全理解.
研究的目的:
- 识别和描述人类造血细胞中的基因促进体和调节元件之间的长距离相互作用.
- 研究这些相互作用的细胞类型特异性和功能意义.
- 在疾病基因发现中利用促进体互动体.
主要方法:
- 使用推广器捕获Hi-C技术.
- 分析了17种人类初级造血细胞类型中的31,253种促进体的相互作用.
主要成果:
- 确定了广泛的细胞类型特异性促进体相互作用.
- 证明了活性促进剂和增强剂之间的相互作用.
- 展示了促进体互动体与造血系的关系.
- 在交互区域中发现基因变异的丰富,
- 连接非编码性疾病变体与假定目标促销者,识别候选疾病基因和途径.
结论:
- 主要细胞促进体互动体为基因组调节机制提供了关键的见解.
- 这种资源对于了解基因调节和识别与疾病相关的基因有价值.
- 这些发现突显了细胞分化过程中核结构的动态性质.
相关概念视频
Epigenetic Regulation
4.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
4.0K
Epigenetic Regulation
34.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
34.1K
Genome-wide Association Studies-GWAS
16.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.4K
Pharmacogenomics: Identification of New Drug Targets
59
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
59
lncRNA - Long Non-coding RNAs
10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
The Eukaryotic Promoter Region
19.3K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
19.3K


